ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ImmunAbs-Inc.

More Like This

PR Newswire associated0

Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now Published

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

HanchorBio Announces First Patient Dosed in the Phase 1 Multi-Regional Clinical Trial of HCB101

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

PR Newswire associated0

ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM

PR Newswire associated0

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023